EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons

Hari Krishnareddy Rachamala iD

Pharmaceutics · 10.10.2025 · 17 (10) · 1315

DOI: 10.3390/pharmaceutics17101315 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 10.10.2025. Verfasst von Hari Krishnareddy Rachamala. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Sciences, Jacksonville, FL 32224, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticles/liposomes (LNPs) represent a highly adaptable nanocarrier system that has gained significant traction in oncology for both therapeutic and diagnostic (theranostic) purposes. Their structural flexibility, biocompatibility, and capacity to encapsulate diverse therapeutic agents ranging from chemotherapeutics to nucleic acids and imaging tracers have enabled targeted cancer treatment with improved efficacy and reduced systemic toxicity. This review critically examines liposome-based platforms across a broad spectrum of cancers, including melanoma, lung, colorectal, liver, breast, ovarian, pancreatic, brain tumors, sarcoma, neuroblastoma, and leukemia. It outlines recent advances in ligand-mediated targeting, pH- and temperature-responsive release systems, and multifunctional LNPs capable of delivering combined therapeutic and imaging payloads. Moreover, the review discusses preclinical outcomes, current clinical trial status, and the challenges hindering clinical translation. By integrating recent innovations and emphasizing translational potential, this work highlights the pivotal role of LNPs in advancing precision cancer therapeutics and diagnostics.

Schlagwörter

Stichwörter der Autor:innen

cancer nanomedicinelipid nanoparticlesliposomestargeted drug deliverytheranosticstranslational oncology

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Sciences, Jacksonville, FL 32224, USA.

ORCID-Profile: Hari Krishnareddy Rachamala

Zitieren

APA

Rachamala, H. K. (2025). Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons. Pharmaceutics, 17(10), 1315. https://doi.org/10.3390/pharmaceutics17101315

Vancouver

Rachamala HK. Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons. Pharmaceutics. 2025;17(10):1315. doi:10.3390/pharmaceutics17101315

BibTeX
@article{Rachamala2025,
  author = {Rachamala, Hari Krishnareddy},
  title = {Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {1315},
  doi = {10.3390/pharmaceutics17101315}
}
Kostenlos starten →